INTRODUCTION: Toxic metal lead is stored in the skeleton and, with increased bone turnover, is mobilized to systemic circulation. Given the bone-conserving properties of estrogens, we hypothesized that current users of estrogen-containing contraception would have lower blood lead concentrations. METHODS: We conducted a cross-sectional analysis using baseline data from the Study of Environment, Lifestyle & Fibroids (SELF). During 2010–2012 (baseline), 1,693 self-identified Black women, ages 23–35, enrolled. Data on contraceptive use were ascertained by interview. We quantified lead concentrations in whole blood using inductively coupled plasma mass spectrometry (ICP-MS). Among 1,555 participants, we estimated the percent difference in blood lead concentrations and 95% CIs between current users and nonusers of estrogen-containing contraception using multivariable linear regression, adjusting for potential confounders. RESULTS: The geometric mean blood lead concentrations for estrogen-containing contraceptive users and nonusers were 0.41 micrograms/dL (95% CI: 0.39, 0.43) and 0.51 micrograms/dL (95% CI: 0.50, 0.52), respectively. After adjustment, current use of estrogen-containing contraception was associated with 10% lower blood lead concentrations (95% CI: −15%, −4%). Considering estrogen-containing contraceptive type, compared to nonusers, combined oral contraceptive users (n=187) had 9% lower blood lead concentrations (95% CI: −15%, −2%) and vaginal ring/transdermal patch users (n=33) had 17% lower blood lead concentrations (95% CI: −29%, −4%). CONCLUSION: As hypothesized, we observed lower blood lead concentrations with current use of estrogen-containing contraception. Further research is warranted to confirm the results and to understand the relationship between lead exposure, hormonal contraception, and bone health to limit systemic lead exposure.
Read full abstract